Stunning presentation.
Looks like massive delays with the GBM trial. Reworking the whole design to include IV delivery for first dose and adding in chemo.
Disappointed we won't see any further GBM results for a long time (probably 2026), especially since the data to date has been so compelling.
CDH17 now officially the lead candidate. The cohort patient numbers are not at all clear. I take it 15 patients is all dose escalation. And then dose expansion - will they make up the phase 2 patient numbers?
- Forums
- ASX - By Stock
- Ann: Investor Presentation
Stunning presentation. Looks like massive delays with the GBM...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
CHM (ASX) Chart |
Day chart unavailable